BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Wang M, Wu HX, Xu RH. Advancing to the era of cancer immunotherapy. Cancer Commun (Lond) 2021. [PMID: 34165252 DOI: 10.1002/cac2.12178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao L, Zhou X, Xie F, Zhang L, Yan H, Huang J, Zhang C, Zhou F, Chen J, Zhang L. Ferroptosis in cancer and cancer immunotherapy. Cancer Communications 2022;42:88-116. [DOI: 10.1002/cac2.12250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
2 Yang X, Wang B, Cao X. Transcriptional suppression of CD8+ T cell exhaustion for improving T cell immunotherapy. Cancer Commun (Lond) 2021. [PMID: 34555272 DOI: 10.1002/cac2.12222] [Reference Citation Analysis]
3 Qu J, Kalyani FS, Liu L, Cheng T, Chen L. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun (Lond) 2021. [PMID: 34713636 DOI: 10.1002/cac2.12224] [Reference Citation Analysis]
4 Zhang Y, Huo L, Wei Z, Tang Q, Sui H. Hotspots and Frontiers in Inflammatory Tumor Microenvironment Research: A Scientometric and Visualization Analysis. Front Pharmacol 2022;13:862585. [PMID: 35370647 DOI: 10.3389/fphar.2022.862585] [Reference Citation Analysis]
5 Lou H, Cao X. Antibody variable region engineering for improving cancer immunotherapy. Cancer Commun (Lond) 2022. [PMID: 35822503 DOI: 10.1002/cac2.12330] [Reference Citation Analysis]
6 Hassanian H, Asadzadeh Z, Baghbanzadeh A, Derakhshani A, Dufour A, Rostami Khosroshahi N, Najafi S, Brunetti O, Silvestris N, Baradaran B. The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. Front Immunol 2022;13:938063. [DOI: 10.3389/fimmu.2022.938063] [Reference Citation Analysis]
7 Zhang B, Chen X, Tang G, Zhang R, Li J, Sun G, Yan X, Fan K. Constructing a nanocage-based universal carrier for delivering TLR-activating nucleic acids to enhance antitumor immunotherapy. Nano Today 2022;46:101564. [DOI: 10.1016/j.nantod.2022.101564] [Reference Citation Analysis]
8 Wang W, Chen X, Li J, Jin Q, Jin HJ, Li X. Hollow MnO 2 Nanoparticles Loaded with Functional Genes as Nanovaccines for Synergistic Cancer Therapy. ACS Appl Nano Mater . [DOI: 10.1021/acsanm.2c01877] [Reference Citation Analysis]
9 Dianat-Moghadam H, Mahari A, Salahlou R, Khalili M, Azizi M, Sadeghzadeh H. Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy. Stem Cell Res Ther 2022;13:150. [PMID: 35395787 DOI: 10.1186/s13287-022-02829-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang W, Zhang Q, Yang N, Shi Q, Su H, Lin T, He Z, Wang W, Guo H, Shen P. Crosstalk between IL-15Rα+ tumor-associated macrophages and breast cancer cells reduces CD8+ T cell recruitment. Cancer Commun (Lond) 2022. [PMID: 35615815 DOI: 10.1002/cac2.12311] [Reference Citation Analysis]
11 Kumar GS, Moustafa M, Sahoo AK, Malý P, Bharadwaj S. Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy. Life 2022;12:659. [DOI: 10.3390/life12050659] [Reference Citation Analysis]
12 Wang M, Yan D, Wang M, Wu Q, Song R, Huang Y, Rao J, Wang D, Zhou F, Tang BZ. A Versatile 980 nm Absorbing Aggregation‐Induced Emission Luminogen for NIR‐II Imaging‐Guided Synergistic Photo‐Immunotherapy Against Advanced Pancreatic Cancer. Adv Funct Materials. [DOI: 10.1002/adfm.202205371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang X, Zhang Q, Cao X. Reversing epigenetic repression of transposable elements for improving tumor immunogenicity. Cancer Commun (Lond) 2022. [PMID: 35001554 DOI: 10.1002/cac2.12261] [Reference Citation Analysis]
14 Wu M, Bai J, Ma C, Wei J, Du X. The Role of Gut Microbiota in Tumor Immunotherapy. J Immunol Res 2021;2021:5061570. [PMID: 34485534 DOI: 10.1155/2021/5061570] [Reference Citation Analysis]
15 Zhang J, Pan S, Jian C, Hao L, Dong J, Sun Q, Jin H, Han X. Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice. Front Immunol 2021;12:819405. [PMID: 35069604 DOI: 10.3389/fimmu.2021.819405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang F, Huang YS, Wu HX, Wang ZX, Jin Y, Yao YC, Chen YX, Zhao Q, Chen S, He MM, Luo HY, Qiu MZ, Wang DS, Wang FH, Xu M, Li YH, Xu RH. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut 2022;71:1340-9. [PMID: 34489309 DOI: 10.1136/gutjnl-2021-324852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Hussain HR, Bashir S, Mahmood A, Sarfraz M, Kanwal M, Ahmad N, Shah HS, Nazir I. Fenugreek seed mucilage grafted poly methacrylate pH-responsive hydrogel: A promising tool to enhance the oral bioavailability of methotrexate. Int J Biol Macromol 2022:S0141-8130(22)00080-0. [PMID: 35041883 DOI: 10.1016/j.ijbiomac.2022.01.064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, Luo HY, Li JB, Wang FH, Qiu MZ, Lv ZD, Wang DS, Li YH, Zhang DS, Xu RH. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Cell Rep Med 2021;2:100383. [PMID: 34622226 DOI: 10.1016/j.xcrm.2021.100383] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chen X, Song E. The theory of tumor ecosystem. Cancer Commun (Lond) 2022. [PMID: 35642770 DOI: 10.1002/cac2.12316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Shramova EI, Shilova MV, Ryabova AV, Dzhalilova DS, Zolotova NA, Telegin GB, Deyev SM, Proshkina GM. Barnase*Barstar-guided two-step targeting approach for drug delivery to tumor cells in vivo. J Control Release 2021;340:200-8. [PMID: 34740723 DOI: 10.1016/j.jconrel.2021.11.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chen YX, Wang ZX, Yuan SQ, Jiang TJ, Huang YS, Xu RH, Wang F, Zhao Q. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy. Clin Transl Med 2021;11:e524. [PMID: 34586735 DOI: 10.1002/ctm2.524] [Reference Citation Analysis]
22 Shahzadi M, Bilal M. CAN A LETHAL PARASITE BE LIFE SAVOR FOR CANCER PATIENTS? GJMS 2022;20:1-2. [DOI: 10.46903/gjms/20.01.1026] [Reference Citation Analysis]